Sodium ibandronate solution
Sodium ibandronate solution is mainly composed of Ibandronate Sodium Monohydrate (HY-B0515).Ibandronate sodium monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate sodium monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate sodium monohydrate inhibits tumor cell proliferation (such as ER+ breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate sodium monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis).
For research use only. We do not sell to patients.
- CAS No.: 138926-19-9
- Formula: C9H24NNaO8P2
- Molecular Weight:359.23
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Chemical Information
-
CAS No. 138926-19-9
-
Molecular Weight 359.23
-
Formula C9H24NNaO8P2
-
SMILES
OC(P(O)(O)=O)(P(O)(O[Na])=O)CCN(C)CCCCC.O
-
Synonyms
BM-210955 solution; RPR-102289A solution
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Journe F, et al. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. Breast Cancer Res. 2006;8(1):R2. [Content Brief]
[2]. Thaler R, et al. Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells. Biochem Pharmacol. 2013 Jan 15;85(2):173-85. [Content Brief]
[3]. Pfister T, et al. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology. 2003 Sep 30;191(2-3):159-67. [Content Brief]
[4]. Russell RG. Ibandronate: pharmacology and preclinical studies. Bone. 2006 Apr;38(4 Suppl 1):S7-12. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Sodium ibandronate solution Related Classifications
HY-FLB0515 Related Classifications
Powered by Bioz